Compare Repligen Corporation Common Stock (RGEN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs NEOS S&P 500 High Income ETF — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while NEOS S&P 500 High Income ETF trades at $53.56 (market cap $12.59B). The key difference: Repligen Corporation Common Stock and NEOS S&P 500 High Income ETF are close in size by market cap, and NEOS S&P 500 High Income ETF is more actively traded (1,834,804 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and NEOS S&P 500 High Income ETF for 59 Days on average.
| RGEN | SPYI | |
|---|---|---|
Market Cap | $11.14B | $12.59B |
Volume | 1,259,263 | 1,834,804 |
Sector | Health | Income / Options Overlay |
52-Week High | $194.57 | $54.42 |
52-Week Low | $102.87 | $47.98 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SPYI trades at $54.11 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights SPYI's role in income-focused portfolios while raising concerns about principal erosion from covered call strategies. The ETF's dividend payments remain consistent with recent distributions around $0.53-0.54 per share.
The outlook for SPYI balances high income generation against capital preservation risks. While the covered call strategy provides attractive yields, investors face potential principal erosion during market rallies. Recent analyst coverage suggests a cautious approach given the trade-offs between income stability and growth limitations inherent in the fund's strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
